The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site
- PMID: 27801970
- DOI: 10.1111/jth.13559
The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site
Erratum in
-
Corrigendum.J Thromb Haemost. 2019 Jul;17(7):1195. doi: 10.1111/jth.14489. J Thromb Haemost. 2019. PMID: 31257734 No abstract available.
Abstract
Essentials The C-terminus of tissue factor pathway inhibitor (TFPIα) binds to the B-domain of factor V (FV). The functional consequences of this interaction were investigated in plasma and model systems. The TFPIα C-terminus inhibited thrombin generation in plasma, but not in the presence of FVa. The TFPIα C-terminus inhibited FV activation by preventing cleavage at Arg1545 .
Summary: Background Factor V (FV) is a carrier and a cofactor of the anticoagulant protein tissue factor pathway inhibitor-α (TFPIα), whose basic C-terminus binds to an acidic region in the B-domain of FV. Proteolysis of FV at Arg709 , Arg1018 and Arg1545 by activated FX (FXa) or thrombin removes the B-domain, and converts FV into a procoagulant cofactor (activated FV [FVa]) of FXa in the prothrombinase complex. However, retention of the acidic region in partially activated FV makes prothrombinase activity susceptible to inhibition by TFPIα. Objective/Methods To investigate the effect of the TFPIα C-terminal peptide (TFPIα C-term) on thrombin generation in plasma and on FV activation in model systems. Results TFPIα C-term inhibited tissue factor-initiated and FXa-initiated thrombin generation in a dose-dependent manner. Failure to inhibit thrombin generation in FV-depleted plasma reconstituted with FVa indicated that the peptide effect was mediated by the acidic region of FV, and was localized at the level of FV activation and/or prothrombinase. In model systems, TFPIα C-term inhibited both FV activation and prothrombinase activity. Western blot analysis showed that the peptide impaired cleavage at Arg1545 by both thrombin and FXa. The inhibition was stronger for FV-short, which binds TFPIα with higher affinity. Similar results were obtained with full-length TFPIα. Conclusions Cleavage of FV at Arg1545 , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIα C-terminus to the FV acidic region. Possible targets of this new anticoagulant function of TFPIα are low-abundance FV(a) species retaining the acidic region.
Keywords: factor V; factor Xa; prothrombinase complex; thrombin; tissue factor pathway inhibitor.
© 2016 International Society on Thrombosis and Haemostasis.
Similar articles
-
Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.J Biol Chem. 2021 Jan-Jun;296:100234. doi: 10.1074/jbc.RA120.016341. Epub 2021 Jan 7. J Biol Chem. 2021. PMID: 33376137 Free PMC article.
-
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.J Thromb Haemost. 2017 Jul;15(7):1241-1250. doi: 10.1111/jth.13665. J Thromb Haemost. 2017. PMID: 28671348 Review.
-
Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.Thromb Haemost. 2018 Jul;118(7):1194-1202. doi: 10.1055/s-0038-1656549. Epub 2018 Jun 4. Thromb Haemost. 2018. PMID: 29864781
-
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.Thromb Haemost. 2020 Jan;120(1):55-64. doi: 10.1055/s-0039-1700516. Epub 2019 Nov 8. Thromb Haemost. 2020. PMID: 31705518
-
Factor V and thrombotic disease: description of a janus-faced protein.Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):530-8. doi: 10.1161/01.atv.0000012665.51263.b7. Arterioscler Thromb Vasc Biol. 2002. PMID: 11950687 Review.
Cited by
-
Basic regions of factor V and tissue factor pathway inhibitor mediate heavy chain and acidic region interactions on factor V revealed by tethered chemical cleavage.J Thromb Haemost. 2025 Aug;23(8):2449-2460. doi: 10.1016/j.jtha.2025.04.028. Epub 2025 May 12. J Thromb Haemost. 2025. PMID: 40368141
-
Factor V east Texas variant causes bleeding in a three-generation family.J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7. J Thromb Haemost. 2022. PMID: 34847292 Free PMC article.
-
Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa.J Thromb Haemost. 2022 Feb;20(2):328-338. doi: 10.1111/jth.15589. Epub 2021 Nov 23. J Thromb Haemost. 2022. PMID: 34773381 Free PMC article.
-
Cryo-EM structure of coagulation factor V short.Blood. 2023 Jun 29;141(26):3215-3225. doi: 10.1182/blood.2022019486. Blood. 2023. PMID: 36862974 Free PMC article.
-
Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell.J Thromb Haemost. 2020 Sep;18(9):2083-2086. doi: 10.1111/jth.14995. Epub 2020 Jul 30. J Thromb Haemost. 2020. PMID: 32729671 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources